Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alpha Tau Medical Ltd (DRTS) recently updated its clinical study titled ‘A Safety and Efficacy Study of Retreatment With Intratumoral Diffusing Alpha Radiation Emitters.’ The study aims to evaluate the safety and efficacy of a novel cancer treatment using intratumoral diffusing alpha radiation emitter devices for treating superficial cutaneous, mucosal, or soft tissue neoplasms. This innovative approach could significantly impact cancer treatment protocols.
The intervention being tested is the Diffusing Alpha Radiation Emitters Therapy (DaRT), which involves inserting a device loaded with Radium-224 into tumors. This device releases short-lived alpha-emitting atoms directly into the tumor, targeting cancer cells.
The study follows an interventional design with a single-group model and no masking, focusing on treatment as its primary purpose. This straightforward design allows for direct observation of the treatment’s effects on participants.
The study commenced on August 18, 2020, and has been completed, with the last update submitted on December 1, 2025. These dates are crucial for tracking the study’s progress and ensuring the data’s relevance and accuracy.
This update could positively influence Alpha Tau Medical’s stock performance by showcasing the company’s commitment to advancing cancer treatment. Investors may view this as a promising development, potentially boosting confidence in the company’s future prospects. In the broader industry context, this study positions Alpha Tau Medical as a competitive player in the innovative cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.